NCT06080776View on ClinicalTrials.gov

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

PHASE3RecruitingINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2031

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

SH-1028 tablets

The initial dose of SH-1028 tablets is 200 mg once daily.

DRUG

Placebo SH-1028 tablets

Placebo SH-1028 tablets.

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Nanjing Sanhome Pharmaceutical, Co., Ltd.

INDUSTRY